ORGO SHAREHOLDER ALERT: Jakubowitz Law Reminds Organogenesis Shareholders of a Lead Plaintiff Deadline of February 8, 2022

NEW YORK, Jan. 28, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Organogenesis Holdings Inc. (NASDAQ: ORGO).

To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/organogenesis-holdings-inc-loss-submission-form/?id=22646&from=4

The lawsuit seeks to recover losses for shareholders who purchased Organogenesis between March 17, 2021 and October 11, 2021

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until February 8, 2022 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, Organogenesis Holdings Inc. issued materially false and/or misleading statements and/or failed to disclose that: (i) Organogenesis improperly billed the federal government for its Affinity and PuraPly XT products by, among other things, setting the price for those products multiple times higher than similar products; (ii) the Company improperly induced doctors to use its Affinity and PuraPly XT products through lucrative reimbursements; (iii) as a result of all the foregoing, the Company's revenue and profits derived from its Affinity and PuraPly XT products were at least in substantial part unsustainable; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE Jakubowitz Law

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED